Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
US Physical Therapy Analyst Ratings and Price Targets | NYSE:USPH | Benzinga
US Physical Therapy Inc has a consensus price target of $109 based on the ratings of 5 analysts. The high is $115 issued by B of A Securities on December 16, 2024. The low is $98 issued by Barrington Research on February 28, 2025. The 3 most-recent analyst ratings were released by JMP Securities, JP Morgan, and Barrington Research on April 22, 2025, March 19, 2025, and February 28, 2025, respectively. With an average price target of $107 between JMP Securities, JP Morgan, and Barrington Research, there's an implied 35.14% upside for US Physical Therapy Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
JP Morgan
Barrington Research
B of A Securities
1calculated from analyst ratings
Analyst Ratings for US Physical Therapy
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/22/2025 | Buy Now | 42.71% | JMP Securities | Constantine Davides39% | $113 → $113 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/19/2025 | Buy Now | 38.92% | JP Morgan | Calvin Sternick50% | $120 → $110 | Maintains | Overweight | Get Alert |
| 02/28/2025 | Buy Now | 23.77% | Barrington Research | Michael Petusky49% | $108 → $98 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | 45.24% | B of A Securities | Joanna Gajuk67% | $100 → $115 | Upgrade | Neutral → Buy | Get Alert |
| 12/16/2024 | Buy Now | 42.71% | JMP Securities | Constantine Davides39% | → $113 | Initiates | → Market Outperform | Get Alert |
| 12/03/2024 | Buy Now | 51.55% | JP Morgan | Calvin Sternick50% | $117 → $120 | Maintains | Overweight | Get Alert |
| 11/21/2024 | Buy Now | 36.4% | Barrington Research | Michael Petusky49% | $108 → $108 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 36.4% | Barrington Research | Michael Petusky49% | $108 → $108 | Maintains | Outperform | Get Alert |
| 10/09/2024 | Buy Now | 36.4% | Barrington Research | Michael Petusky49% | $108 → $108 | Maintains | Outperform | Get Alert |
| 10/07/2024 | Buy Now | 13.67% | B of A Securities | Joanna Gajuk67% | $114 → $90 | Downgrade | Buy → Neutral | Get Alert |
| 09/20/2024 | Buy Now | 36.4% | Barrington Research | Michael Petusky49% | $108 → $108 | Maintains | Outperform | Get Alert |
| 08/15/2024 | Buy Now | 36.4% | Barrington Research | Michael Petusky49% | $122 → $108 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 54.08% | Barrington Research | Michael Petusky49% | $122 → $122 | Maintains | Outperform | Get Alert |
| 03/13/2024 | Buy Now | 47.76% | JP Morgan | Calvin Sternick50% | $99 → $117 | Maintains | Overweight | Get Alert |
| 03/01/2024 | Buy Now | 54.08% | Barrington Research | Michael Petusky49% | $120 → $122 | Maintains | Outperform | Get Alert |
| 01/03/2024 | Buy Now | 51.55% | Barrington Research | Michael Petusky49% | $111 → $120 | Maintains | Outperform | Get Alert |
| 11/17/2023 | Buy Now | 25.03% | JP Morgan | Calvin Sternick50% | $108 → $99 | Maintains | Overweight | Get Alert |
| 11/09/2023 | Buy Now | 40.19% | Barrington Research | Michael Petusky49% | $124 → $111 | Maintains | Outperform | Get Alert |
| 09/22/2023 | Buy Now | 36.4% | JP Morgan | Calvin Sternick50% | → $108 | Initiates | → Overweight | Get Alert |
| 09/19/2023 | Buy Now | — | CJS Securities | Larry Solow49% | — | Upgrade | Market Perform → Market Outperform | Get Alert |
| 08/14/2023 | Buy Now | 56.61% | Barrington Research | Michael Petusky49% | $116 → $124 | Maintains | Outperform | Get Alert |
| 06/30/2023 | Buy Now | 74.29% | B of A Securities | Joanna Gajuk67% | → $138 | Initiates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 46.5% | Barrington Research | Michael Petusky49% | $110 → $116 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 38.92% | Barrington Research | Michael Petusky49% | $107 → $110 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for US Physical Therapy (USPH) stock?
The latest price target for US Physical Therapy (NYSE:USPH) was reported by JMP Securities on April 22, 2025. The analyst firm set a price target for $113.00 expecting USPH to rise to within 12 months (a possible 42.71% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for US Physical Therapy (USPH)?
The latest analyst rating for US Physical Therapy (NYSE:USPH) was provided by JMP Securities, and US Physical Therapy reiterated their market outperform rating.
When was the last upgrade for US Physical Therapy (USPH)?
The last upgrade for US Physical Therapy Inc happened on December 16, 2024 when B of A Securities raised their price target to $115. B of A Securities previously had a neutral for US Physical Therapy Inc.
When was the last downgrade for US Physical Therapy (USPH)?
The last downgrade for US Physical Therapy Inc happened on October 7, 2024 when B of A Securities changed their price target from $114 to $90 for US Physical Therapy Inc.
When is the next analyst rating going to be posted or updated for US Physical Therapy (USPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of US Physical Therapy, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for US Physical Therapy was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.
Is the Analyst Rating US Physical Therapy (USPH) correct?
While ratings are subjective and will change, the latest US Physical Therapy (USPH) rating was a reiterated with a price target of $113.00 to $113.00. The current price US Physical Therapy (USPH) is trading at is $79.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
